Ced or metastatic lung squamous cell carcinoma

Hong Shen,J. Zhao,Shan,S. Weng,Xue,F. Fang,Yi,Yangling Zhang,Jian,Jin Huang

2016-01-01

Abstract:Lung cancer is one of the most common and aggressive malignancies in the world. More than million patients are newly diagnosed every year globally. The five-year survival rate is less than 15%. High incidence and poor prognosis made it the leading causes of cancer related mortality. Nonsmall cell lung cancer (NSCLC) accounts for 80% to 85% of lung cancer cases. 25% to 30% of patients with NSCLC are in locally advanced stage, 40% to 50% of patients have distant metastases when they were diagnosed which were unresectable. In NSCLC, squamous cell lung cancer accounts for 29%. Because of the low rate of epidermal growth factor receptor (EGFR) mutation, The platinumbased doublet chemotherapy is considered as the first-line standard therapy, but the benefit is limited. Novel regimens are needed urgently to improve outcome, such as the anti-angiogenesis therapy. Endostar (YH-16) is a novel recombinant human endostatin developed by China. Compared to the rh-endostatin reported previously, an additional nine-amino acid sequence (MGGSHHHHH) was added at the N-terminal of the protein, which simplified the purification and improved the stability of the protein. In 2005, Wang et al. published the results of stage III clinical trial which showed the combination of Endostar with vinorelbine plus Acta Medica Mediterranea, 2016, 32: 57